布地奈德联合氨溴索治疗慢性阻塞性肺疾病急性加重期疗效观察.docVIP

布地奈德联合氨溴索治疗慢性阻塞性肺疾病急性加重期疗效观察【摘要】 目的 探讨布地奈德混悬液联合氨溴索雾化吸入治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效。方法 选择急性加重期的COPD患者160例，按入院先后顺序分为观察组与对照组，每组各80例。对照组给予持续低流量吸氧、抗感染、平喘、止咳化痰及维持水电解质酸碱平衡等常规治疗。观察组在常规治疗的基础上，给予布地奈德混悬液联合氨溴索雾化吸入。观察比较两组各项临床疗效指标。结果 观察组总有效率为95.0％，对照组总有效率为81.25％，两组比较差异有统计学意义(?P?0.05)。观察组无明显不良反应发生。结论 布地奈德联合氨溴索雾化吸入治疗COPD急性加重期疗效好，无明显不良反应，值得临床推广使用。? 【关键词】 慢性阻塞性肺疾病； 急性加重期； 布地奈德； 氨溴索； 雾化吸入?? Clinical efficacy of Budesonide combined with ambroxol in treatment of chronic obstructive pulmonary disease with acute exacerbation ?LIAO Bing,WEI Mao-gang,LUO Ling-cheng,CHEN Dan.Leshan People?s Hospital, Leshan 614000,China?? 【Abstract】 Objective To explore the clinical efficacy of aerosol inhalation of budesonide uspension combined with ambroxol in treatment of chronic obstructive pulmonary disease patients with acute exacerbation.Methods According to the order of admission,160 patients with acute exacerbation of COPD were divided into observation group and control group,each group was 80 cases.Control group was given continuous low flow oxygen, antibiotics,asthma and cough and phlegm and maintaining water and electrolyte acid-base balance and other conventional treatment.On the basis of conventional therapy,the observation group was given aerosol inhalation of budesonide uspension combined with ambroxol.The clinical indicators are observed and compared.Results The total efficiency of observation group was 95.0% and the control group was 81.25%,the difference was significant between the groups(?P?0.05).Observed group has no adverse reactions.Conclusion Aerosol inhalation of budesonide combined with ambroxol in treatment of acute exacerbation of COPD has good efficacy,no adverse reactions, is worthy of clinical use.? 【Key words】 Chronic obstructive pulmonary disease; Acute exacerbation; Budesonide; Ambroxol; Aerosol inhalation ?? 慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)在我国40岁以上人群的患病率为8.2％，居全球死亡原因的第4位，多数患者死于急性加重期［1］。本研究应用氨溴索联合布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重期的患者，取得了较好的效果。现报告如下